Who is sponsoring NCT06093698?

NCT06093698 is sponsored by ITabMed Co., Ltd..

What drugs are being tested in NCT06093698?

Interventions in NCT06093698: Recombinant Anti-EpCAM-CD3 Antibody Injection.

What condition does NCT06093698 study?

NCT06093698 studies Recurrent or Metastatic Solid Tumors.

Is NCT06093698 still recruiting?

NCT06093698 is currently not yet recruiting. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT06093698: A-337

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Not yet recruiting Phase 1 Last updated 23 October 2023

What this trial tests

Phase 1 trial testing Recombinant Anti-EpCAM-CD3 Antibody Injection in Recurrent or Metastatic Solid Tumors in 94 participants. Not yet recruiting.

Timeline

1 December 2023

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	ITabMed Co., Ltd.
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	94
Start date	1 December 2023
Primary completion	30 June 2026
Estimated completion	31 December 2026

Drugs / interventions tested

Recombinant Anti-EpCAM-CD3 Antibody Injection — full drug profile →

Conditions studied

Recurrent or Metastatic Solid Tumors — all drugs for Recurrent or Metastatic Solid Tumors →

Sponsor

ITabMed Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Recurrent or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current landscape of T-cell engagers in early-phase clinical development in solid cancers.
Spinazzola A, Iannantuono GM, Gulley JL, Giudice E, et al · · 2025 · cited 3× · PMID 41122165 · DOI 10.3389/fimmu.2025.1665838

Verify or expand the search:

Other recruiting trials for Recurrent or Metastatic Solid Tumors

Currently open trials in the same condition.

NCT07015697 — A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors · Phase 1 · recruiting
NCT06330064 — A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06093698 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ITabMed Co., Ltd.
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06093698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing